These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9106763)

  • 1. Increased dopamine activity associated with stuttering.
    Wu JC; Maguire G; Riley G; Lee A; Keator D; Tang C; Fallon J; Najafi A
    Neuroreport; 1997 Feb; 8(3):767-70. PubMed ID: 9106763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain--an approach using MRI-aided spatial normalization.
    Nagano AS; Ito K; Kato T; Arahata Y; Kachi T; Hatano K; Kawasumi Y; Nakamura A; Yamada T; Abe Y; Ishigaki T
    Neuroimage; 2000 Jun; 11(6 Pt 1):760-6. PubMed ID: 10860800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies arising from recent FDOPA articles.
    Cumming P; Gjedde A; Reith J
    J Nucl Med; 1997 Aug; 38(8):1267-71. PubMed ID: 9255163
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine in amygdala gates limbic processing of aversive stimuli in humans.
    Kienast T; Hariri AR; Schlagenhauf F; Wrase J; Sterzer P; Buchholz HG; Smolka MN; Gründer G; Cumming P; Kumakura Y; Bartenstein P; Dolan RJ; Heinz A
    Nat Neurosci; 2008 Dec; 11(12):1381-2. PubMed ID: 18978778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
    Nagasawa H; Tanji H; Itoh M; Itoyama Y
    Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli.
    Siessmeier T; Kienast T; Wrase J; Larsen JL; Braus DF; Smolka MN; Buchholz HG; Schreckenberger M; Rösch F; Cumming P; Mann K; Bartenstein P; Heinz A
    Eur J Neurosci; 2006 Jul; 24(1):305-13. PubMed ID: 16882026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal 18F-dopa uptake: absence of an aging effect.
    Eidelberg D; Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Margouleff D; Moeller JR; Patlak CS; Fahn S
    J Cereb Blood Flow Metab; 1993 Sep; 13(5):881-8. PubMed ID: 8360294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine during sensorial stimulations: a [18F]FDOPA PET study in human and cats.
    Hassoun W; Thobois S; Ginovart N; Garcia-Larrea L; Cavorsin ML; Guillouet S; Bonnefoi F; Costes N; Lavenne F; Martin JP; Broussolle E; Leviel V
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):63-7. PubMed ID: 15936513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal.
    Wu JC; Bell K; Najafi A; Widmark C; Keator D; Tang C; Klein E; Bunney BG; Fallon J; Bunney WE
    Neuropsychopharmacology; 1997 Dec; 17(6):402-9. PubMed ID: 9397428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
    Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
    Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
    Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
    Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
    Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.
    Vernaleken I; Kumakura Y; Cumming P; Buchholz HG; Siessmeier T; Stoeter P; Müller MJ; Bartenstein P; Gründer G
    Neuroimage; 2006 May; 30(4):1332-9. PubMed ID: 16439159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic modeling of PET data: quantitative conflict and challenge.
    Ichise M; Ballinger JR
    J Nucl Med; 1997 Aug; 38(8):1266-7. PubMed ID: 9255162
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and preliminary evaluation of (S)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous system.
    Yost Y; Conway T
    Nucl Med Biol; 1996 Oct; 23(7):857-65. PubMed ID: 8971852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.
    Meyer-Lindenberg A; Miletich RS; Kohn PD; Esposito G; Carson RE; Quarantelli M; Weinberger DR; Berman KF
    Nat Neurosci; 2002 Mar; 5(3):267-71. PubMed ID: 11865311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.